SELLAS Announces FDA Rare Pediatric Disease Designation for Its Leukemia Treatment

Seeking AlphaOct 15 21:34

Express News | Sellas Life Sciences Group Inc - Gps Phase 3 Regal Trial Interim Analysis Expected in Q4 2024

BreakingsOct 15 20:45

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

GlobeNewswireOct 15 20:45

Express News | Sellas Announces U.S. FDA Rare Pediatric Disease Designation (Rpdd) Granted to Galinpepimut-S (Gps) for the Treatment of Pediatric Acute Myeloid Leukemia

BreakingsOct 15 20:45

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

GlobeNewswireOct 11 04:05

Sellas Life Sciences Group Inc (NASDAQ:SLS): A Bull Case Theory

Yahoo FinanceSep 19 03:09